viktar
2021-07-02
Great news!!!
J&J Covid-19 Vaccine Shows Promising Preliminary Signs of Protecting Against Delta Variant
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
4
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":156842943,"tweetId":"156842943","gmtCreate":1625214061982,"gmtModify":1631893390848,"author":{"id":4087130985557480,"idStr":"4087130985557480","authorId":4087130985557480,"authorIdStr":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":8,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Great news!!!</p></body></html>","htmlText":"<html><head></head><body><p>Great news!!!</p></body></html>","text":"Great news!!!","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/156842943","repostId":1190296598,"repostType":4,"repost":{"id":"1190296598","kind":"news","pubTimestamp":1625213296,"share":"https://www.laohu8.com/m/news/1190296598?lang=&edition=full","pubTime":"2021-07-02 16:08","market":"us","language":"en","title":"J&J Covid-19 Vaccine Shows Promising Preliminary Signs of Protecting Against Delta Variant","url":"https://stock-news.laohu8.com/highlight/detail?id=1190296598","media":"The Wall Street Journal","summary":"Vaccine triggered strong immune response in blood samples from eight vaccinated people.\n\nJohnson & J","content":"<blockquote>\n Vaccine triggered strong immune response in blood samples from eight vaccinated people.\n</blockquote>\n<p>Johnson & Johnson’sJNJ0.74%Covid-19 vaccine showed promising signs in a small laboratory study of protecting against the Delta variant spreading across the U.S. and other countries, the company said.</p>\n<p>In laboratory testing, the vaccine triggered a strong immune response in blood samples taken from eight vaccinated people, J&J said Thursday.</p>\n<p>The positive performance adds to a growing set of evidence indicating currently authorized Covid-19 vaccines can safeguard against the Delta variant, which appears to be more contagious than earlier strains.</p>\n<p>How well the J&J shot fares against the Delta variant has been closely watched by health authorities around the world.</p>\n<p>Many countries have been counting on supplies, especially because the vaccine is simpler to ship, handle and store than the shots fromPfizerInc.PFE1.02%and its partnerBioNTech SEBNTX0.05%and fromModernaInc.MRNA0.06%</p>\n<p>The new findings “reinforce the ability of the Johnson & Johnson Covid-19 vaccine to help protect the health of people globally,” said J&J Chief Scientific Officer Paul Stoffels.</p>\n<p>J&J also said its vaccine, in a separate study, generated immune responses against Covid-19 lasting for at least eight months, the most time that researchers were able to study the shot’s durability.</p>\n<p>J&J, of New Brunswick, N.J., released the high-level findings in a news release, not a detailed and peer-reviewed study.</p>\n<p>The Delta variant first emerged in India late last year. Since then, it has spread rapidly, becoming the most common strain of the Covid-19 virus in several countries,including the U.S.</p>\n<p>The variant made up about 40% of positive Covid-19 test samples as of June 27, according to population genomics company Helix OpCo LLC, which collects and analyzes test samples from several U.S. states.</p>\n<p>Vaccination is the best defense against the Delta variant, according to public-health authorities, who have cited the threat posed by the strain in urging people to get immunized.</p>\n<p>So far, studies have indicated various vaccines appear effective against the Delta strain, especially once individuals have been fully vaccinated, though the shots aren’t as protective as they are against the original virus.</p>\n<p>Separate studies in England and Scotland found that vaccines from Pfizer-BioNTech andAstraZenecaPLCoffered substantial protection from the Delta variantagainst severe cases of Covid-19 and hospitalization.</p>\n<p>England’s public health agency said an analysis of 14,000 cases found the Pfizer-BioNTech shot reduced the risk of hospitalization after infection with Delta by 96%.</p>\n<p>J&J’s single-dose shot is based on a different technology than the Pfizer-BioNTech and Moderna vaccines, but operates similar to AstraZeneca’s.</p>\n<p>J&J’s shot uses a modified version of the virus responsible for the common cold, to carry genetic instructions teaching cells how to make the spike protein that juts from the surface of the coronavirus.</p>\n<p>Production of the spike protein, in turn,prompts the immune system to develop molecular defensesagainst the coronavirus.</p>\n<p>In its large, pivotal study, the J&J vaccine was 66% effective in protecting against Covid-19 and 85% effective against severe disease. The shot appeared to be less effective in South Africa, where the variant now called Beta was circulating.</p>\n<p>Overall, however, it was highly effective in places where variants were spreading during the trial.</p>\n<p>J&J said the immune response found in its recent laboratory study was higher for the Delta variant than for Beta.</p>\n<p>The study looked at blood samples from eight people in the J&J vaccine’s Phase 3 trial. The study found the shot triggered strong levels of neutralizing antibodies, agents of the immune system thought to be most effective fighting viruses.</p>\n<p>Data on the durability of the vaccine’s protection came from a separate small study by Dan Barouch, an immunologist at Beth Israel Deaconess Medical Center in Boston who helped develop the J&J vaccine.</p>\n<p>The study found that strong neutralizing-antibody and other immune responses to Covid-19, including to the Delta strain, persisted for the eight months examined, J&J said.</p>\n<p>The U.S. Food and Drug Administrationauthorized J&J’s shotin February.</p>\n<p>In April, federal health authorities temporarily recommended pausing use of J&J’s vaccine while they investigated a blood-clotting condition among people who got the shot.</p>\n<p>Theauthorities lifted the pauseshortly after, however, saying the benefits of the vaccine outweighed the risk and issuing recommendations for treating the rare condition.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>J&J Covid-19 Vaccine Shows Promising Preliminary Signs of Protecting Against Delta Variant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJ&J Covid-19 Vaccine Shows Promising Preliminary Signs of Protecting Against Delta Variant\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-02 16:08 GMT+8 <a href=https://www.wsj.com/articles/j-j-covid-19-vaccine-shows-promising-preliminary-signs-of-protecting-against-delta-variant-11625184011?mod=business_lead_pos2><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vaccine triggered strong immune response in blood samples from eight vaccinated people.\n\nJohnson & Johnson’sJNJ0.74%Covid-19 vaccine showed promising signs in a small laboratory study of protecting ...</p>\n\n<a href=\"https://www.wsj.com/articles/j-j-covid-19-vaccine-shows-promising-preliminary-signs-of-protecting-against-delta-variant-11625184011?mod=business_lead_pos2\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.wsj.com/articles/j-j-covid-19-vaccine-shows-promising-preliminary-signs-of-protecting-against-delta-variant-11625184011?mod=business_lead_pos2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190296598","content_text":"Vaccine triggered strong immune response in blood samples from eight vaccinated people.\n\nJohnson & Johnson’sJNJ0.74%Covid-19 vaccine showed promising signs in a small laboratory study of protecting against the Delta variant spreading across the U.S. and other countries, the company said.\nIn laboratory testing, the vaccine triggered a strong immune response in blood samples taken from eight vaccinated people, J&J said Thursday.\nThe positive performance adds to a growing set of evidence indicating currently authorized Covid-19 vaccines can safeguard against the Delta variant, which appears to be more contagious than earlier strains.\nHow well the J&J shot fares against the Delta variant has been closely watched by health authorities around the world.\nMany countries have been counting on supplies, especially because the vaccine is simpler to ship, handle and store than the shots fromPfizerInc.PFE1.02%and its partnerBioNTech SEBNTX0.05%and fromModernaInc.MRNA0.06%\nThe new findings “reinforce the ability of the Johnson & Johnson Covid-19 vaccine to help protect the health of people globally,” said J&J Chief Scientific Officer Paul Stoffels.\nJ&J also said its vaccine, in a separate study, generated immune responses against Covid-19 lasting for at least eight months, the most time that researchers were able to study the shot’s durability.\nJ&J, of New Brunswick, N.J., released the high-level findings in a news release, not a detailed and peer-reviewed study.\nThe Delta variant first emerged in India late last year. Since then, it has spread rapidly, becoming the most common strain of the Covid-19 virus in several countries,including the U.S.\nThe variant made up about 40% of positive Covid-19 test samples as of June 27, according to population genomics company Helix OpCo LLC, which collects and analyzes test samples from several U.S. states.\nVaccination is the best defense against the Delta variant, according to public-health authorities, who have cited the threat posed by the strain in urging people to get immunized.\nSo far, studies have indicated various vaccines appear effective against the Delta strain, especially once individuals have been fully vaccinated, though the shots aren’t as protective as they are against the original virus.\nSeparate studies in England and Scotland found that vaccines from Pfizer-BioNTech andAstraZenecaPLCoffered substantial protection from the Delta variantagainst severe cases of Covid-19 and hospitalization.\nEngland’s public health agency said an analysis of 14,000 cases found the Pfizer-BioNTech shot reduced the risk of hospitalization after infection with Delta by 96%.\nJ&J’s single-dose shot is based on a different technology than the Pfizer-BioNTech and Moderna vaccines, but operates similar to AstraZeneca’s.\nJ&J’s shot uses a modified version of the virus responsible for the common cold, to carry genetic instructions teaching cells how to make the spike protein that juts from the surface of the coronavirus.\nProduction of the spike protein, in turn,prompts the immune system to develop molecular defensesagainst the coronavirus.\nIn its large, pivotal study, the J&J vaccine was 66% effective in protecting against Covid-19 and 85% effective against severe disease. The shot appeared to be less effective in South Africa, where the variant now called Beta was circulating.\nOverall, however, it was highly effective in places where variants were spreading during the trial.\nJ&J said the immune response found in its recent laboratory study was higher for the Delta variant than for Beta.\nThe study looked at blood samples from eight people in the J&J vaccine’s Phase 3 trial. The study found the shot triggered strong levels of neutralizing antibodies, agents of the immune system thought to be most effective fighting viruses.\nData on the durability of the vaccine’s protection came from a separate small study by Dan Barouch, an immunologist at Beth Israel Deaconess Medical Center in Boston who helped develop the J&J vaccine.\nThe study found that strong neutralizing-antibody and other immune responses to Covid-19, including to the Delta strain, persisted for the eight months examined, J&J said.\nThe U.S. Food and Drug Administrationauthorized J&J’s shotin February.\nIn April, federal health authorities temporarily recommended pausing use of J&J’s vaccine while they investigated a blood-clotting condition among people who got the shot.\nTheauthorities lifted the pauseshortly after, however, saying the benefits of the vaccine outweighed the risk and issuing recommendations for treating the rare condition.","news_type":1},"isVote":1,"tweetType":1,"viewCount":104,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":12,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/156842943"}
精彩评论